Compound May Fight Hard-to-Treat Lung Cancer
December 29th, 2009
Scientists at the Dana-Farber Cancer Institute say they have developed a compound that may be capable of halting a common type of drug-resistant lung cancer.
Their study is published in the Dec. 24/31 issue of the journal Nature.
The researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release. That protein is known as an epidermal growth factor receptor (EGFR) kinase.